People in the News

People in the News

(Page
1
of
1)

Click Image To Enlarge +

Michael J. Harrington

Eli Lilly promoted Michael J. Harrington to svp and general counsel. Formerly, Harrington was vp and deputy general counsel. Other positions he held at the company include managing director of Eli Lilly New Zealand, general counsel for Lilly’s Asia-Pacific operations, and deputy general counsel.

NicOx appointed Jason Menzo as director of marketing and Mark Puwal as national director of sales...Polynoma added Sara Zaknoen, M.D., as CMO, Andrew Buckland as CFO, and Patrick Mallon as COO...med fusion hired Kristen Champion, Ph.D., as technical director of molecular pathology, Neelam Dhiman, Ph.D., as technical director of microbiology, and Vivek Kumar, Ph.D., as technical director of chemistry and toxicology.

Click Image To Enlarge +

Joseph Rogers, Ph.D.

Joseph Rogers, Ph.D., joined SRI International’s biosciences division as executive director of health science. Prior to SRI, Rogers was founder and president of the Sun Health Research Institute. He also served on boards including the American Geriatrics Society, and Arizona Alzheimer’s Assoc.

Mark McDonough is now CCO at CombiMatrix...Ceres named Steven E. Koonin, Ph.D., to its board of directors...Actinium Pharmaceuticals hired Enza Guagenti as CFO and Jack V. Talley as president and CEO...biOasis Technologies appointed Terry Pearson, Ph.D., Chris Fibiger, Ph.D., Michael Hutchison, Ron Erickson, and Greg Gubitz to its board of directors and elected Robin Hutchison as president and CEO and David Clark as CFO and corporate secretary.

Click Image To Enlarge +

Christine Mayer

VaxInnate added Christine Mayer as vp of business development. Previously, Mayer was svp of business development at Biovail Pharmaceuticals. Prior to that, she held senior positions at Sanofi Aventis and Johnson & Johnson.

VaxInnate added Katalin Abraham as vp of regulatory affairs. Abraham formerly served as director of regulatory affairs at GlaxoSmithKline. Before joining GSK, she held senior positions at Merck and Centocor, now known as Janssen Biotech.

Syngenea added Martin Biggs, Ph.D., as sales manager for U.K. and Ireland and Rob van den Broek as European sales manager...Oxford Gene Technology appointed Peter Rigby as chairman of its scientific advisory board...Pulmatrix named Robert Clarke, Ph.D., as CEO...Stuart A. Arbuckle is the new CCO at Vertex...Codexis added David O’Toole as CFO.

Click Image To Enlarge +

Faheem Hasnain

Aragon Pharmaceuticals appointed Faheem Hasnain as an independent director to its board of directors. Hasnain is currently president and CEO of Receptos. He has also held executive and leadership roles at Facet Biotech, PDL BioPharma, Biogen Idec, Bristol Myers-Squibb, and GlaxoSmithKline.

Islet Sciences appointed Richard A. Franco,Sr. to its board of directors and Kevan Herold, M.D., and Morton Printz, Ph.D., to its scientific advisory board...Aushon BioSystems hired Martin Verhoef as CEO...Patrick Vink, M.D., joined Cubist Pharmaceuticals as svp and general manager of international business.

Click Image To Enlarge +

Jonathan DiVincenzo

Jonathan DiVincenzo is now president and CEO at Enzymatics. Most recently, he worked at Millipore as corporate officer and president of its bioscience division. Previous positions held by DiVincenzo include product manager at Orion Research and technical support engineer for GE.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.